GALWAY, IRELAND--January 22, 2024--Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--Buoyed by the runaway success of its diabetes and weight loss drugs Ozempic and Wegovy, Denmark's Novo Nordisk A/S (NYSE:NVO) (Bagsværd, Denmark) has plans to build a major manufacturing operation at its Grange Castle campus in Dublin, Ireland.

Within this article: Details new plant investment in Dublin to boost production of Ozempic and Wegovy, scale, timeline, related European investments